Skip to main content

LINFOMAS AGRESIVOS: TERAPIA GUIADA POR EL DIAGNOSTICO MOLECULAR

SAF2013-47416-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2013
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION MARQUES DE VALDECILLA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma

  • Alonso Alonso, Ruth
  • Mondéjar, Rufino
  • Martínez, Nerea
  • García Diaz, Nuria
  • Pérez, Cristina
  • Merino, David
  • Rodríguez, Marta
  • Esteve-Codina, Anna
  • Fusté, Berta
  • Gut, Marta
  • Burrows, Francis
  • Scholz, Catherine
  • Vaqué, José Pedro
  • Gualberto, Antonio
  • Piris, Miguel A.
Patients diagnosed with T-cell leukemias and T-cell lymphomas (TCLs) still have a poor prognosis and an inadequate response to current therapies, highlighting the need for targeted treatments. We have analyzed the potential therapeutic value of the farnesyltransferase inhibitor, tipifarnib, in 25 TCL cell lines through the identification of genomic and/or immunohistochemical markers of tipifarnib sensitivity. More than half of the cell lines (60%) were considered to be sensitive. Tipifarnib reduced cell viability in these T-cell leukemia and TCL cell lines, induced apoptosis and modified the cell cycle. A mutational study showed TP53, NOTCH1 and DNMT3 to be mutated in 84.6%, 69.2% and 30.0% of sensitive cell lines, and in 62.5%, 0% and 0% of resistant cell lines, respectively. An immunohistochemistry study showed that p-ERK and RelB were associated as potential biomarkers of tipifarnib sensitivity and resistance, respectively. Data from RNA-seq show that tipifarnib at IC50 after 72 h downregulated a great variety of pathways, including those controlling cell cycle, metabolism, and ribosomal and mitochondrial activity. This study establishes tipifarnib as a potential therapeutic option in T-cell leukemia and TCL. The mutational state of NOTCH1, p-ERK and RelB could serve as potential biomarkers of tipifarnib sensitivity and resistance., The research was supported by grants from the Instituto de Salud Carlos III, from the Ministerio de Economía, Industria y Competitividad [SAF2013-47416-R, CIBERONC-ISCIII, ISCIII-MINECO-AES-FEDER (Plan Estatal I + D + I 2013–2016)}.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Clonal dynamics monitoring during clinical evolution in chronic lymphocytic leukaemia

  • González-Rincón, Julia
  • Gómez, Sagrario
  • Martinez, Nerea
  • Troulé, Kevin
  • Perales-Patón, Javier
  • Derdak, Sophia
  • Beltran, Sergi
  • Fernández-Cuevas, Belén
  • Pérez-Sanz, Nuria
  • Nova-Gurumeta, Sara
  • Gut, Ivo Glynne
  • Al-Shahrour, Fátima
  • Piris, Miguel A.
  • García-Marco, J. A.
  • Sánchez-Beato, Margarita
Chronic lymphocytic leukaemia is the most prevalent leukaemia in Western countries. It is an incurable disease characterized by a highly variable clinical course. Chronic lymphocytic leukaemia is an ideal model for studying clonal heterogeneity and dynamics during cancer progression, response to therapy and/or relapse because the disease usually develops over several years. Here we report an analysis by deep sequencing of sequential samples taken at different times from the affected organs of two patients with 12- and 7-year disease courses, respectively. One of the patients followed a linear pattern of clonal evolution, acquiring and selecting new mutations in response to salvage therapy and/or allogeneic transplantation, while the other suffered loss of cellular tumoral clones during progression and histological transformation., This work was supported by the Spanish Ministry of Economy and Competence (MINECO): SAF2013-47416-R; ISCIII-MINECO AES-FEDER (Plan Estatal de I + D + I 2008–2011 and 2013–2016) (PI14/00221 (MSB), PIE14/0064 (MSB), PIE15/0081 (MAP), PI16/01294 (MAP), CIBERONC CB16/12/00291 (MAP)), Madrid Autonomous Community, B2017/BMD3778 (MAP, MSB, FA-S), F Hoffmann-La Roche (JAGM); CNIO Bioinformatics Unit work has been supported by Marie-Curie Career Integration Grant CIG334361. J.G.-R. is a recipient of a i-PFIS predoctoral fellowship (IFI14/00003); NM was supported by AECC Scientific Foundation; S.D. was supported by the Torres Quevedo subprogramme (MICINN) under grant agreement PTQ-12-05391. K.T. and J.P.-P. are supported by Severo Ochoa FPI grant doctoral fellowship by the Spanish MINECO. MSB currently holds a Miguel Servet II contract (CPII16/00024) supported by ISCIII-MINECO AES-FEDER (Plan Estatal I + D + I 2013–2016) and the Fundación de Investigación Biomédica Puerta de Hierro.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations

  • Curiel-Olmo, Soraya
  • Vaqué, José P.
  • Piris, Miguel A.
  • Martínez, Nerea
Letter to Blood.-- Curiel-Olmo, Soraya et al., Splenic diffuse red pulp lymphoma (SDRPL) is a rare small B-cell neoplasm provisionally included in the category of unclassifiable splenic B-cell lymphomas/leukemias in the 2008 World Health Organization classification. SDRPL is characterized by a diffuse pattern of involvement of the splenic red pulp by small monomorphous B lymphocytes., This work was supported by grants from the Ministerio de Economía, Industria y Competitividad (RTICC RD06/0020/0107, RD12/0036/0060, PI 12/1682, PT13/ 0010/0007, PI16/01294, SAF2013-47416-R, CIBERONC-ISCIII, PIE15/0081) and the Asociación Española Contra el Cáncer, Spain. S.D. was supported by the Torres Quevedo subprogramme (Ministerio de Economía y Competitividad [MICINN]) under grant agreement PTQ-12-05391., Peer Reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Reseña (Review)

CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies

  • Prieto-Torres, L.
  • Rodriguez-Pinilla, S.M.
  • Onaindia, A.
  • Ara, M.
  • Requena, L.
  • Piris, M.Á.
Primary cutaneous CD30-positive T-cell lymphoproliferative disorders are the second most common subgroup of cutaneous T-cell lymphomas. They include two clinically different entities with some overlapping features and borderline cases: lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Molecular studies of primary cutaneous anaplastic large cell lymphoma reveal an increasing level of heterogeneity that is associated with histological and immunophenotypic features of the cases and their response to specific therapies. Here, we review the most significant genetic, epigenetic and molecular alterations described to date in primary cutaneous CD30-positive T-cell lymphoproliferative disorders, and their potential as therapeutic targets.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Two independent consecutive lymphoma cases carry an identical MYD88 mutation but differ in their IGVH rearrangement

  • Prieto-Torres, L
  • Trascasa, A
  • Manso, R
  • Machan, S
  • Cieza-Diaz, D
  • Olmedilla, G
  • Garcia-Garcia, M
  • Ara-Martin, M
  • Requena, L
  • Piris, MA
  • Rodriguez-Pinilla, SM
Several studies have provided evidence of the presence of lymphoma stem cells by showing the apparent transmission of premalignant lymphoid cells in allogeneic bone marrow transplantation, where the donor and recipient develop the same lymphoid disease.1-6 The lymphoid neoplasms do not develop at the same time, and in some cases, a different immunoglobulin heavy chain (IgH) rearrangement occurs in the two tumours. These data support the theory of a common lymphoma precursor cell (CPC) and make it less likely that it is due to a circulating donor tumour cell. Recently, Hattori et al.7 published genetic evidence of CPC in primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL), suggesting that intra- and extra-CNS tumours in the same patient are derived from CPC with myeloid differentiation factor 88 (MYD88) L265P gene mutations, which arise before or after the IgH rearrangement. They suggested that CPC maps to different positions during B-lineage differentiation. The position after IgH rearrangement and even after hypermutation at the variable region could explain the appearance of clonally related lymphomas, whereas the emergence of CPC before IgH rearrangement might account for the presence of clonally unrelated B-cell lymphomas in the same patient because divergence may occur before the Variable-Diversity-Junctional (VDJ) rearrangements.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Clonal dynamics monitoring during clinical evolution in chronic lymphocytic leukaemia

  • González-Rincón, Julia
  • Gómez, Sagrario
  • Martinez, Nerea
  • Troulé, Kevin
  • Perales-Patón, Javier
  • Derdak, Sophia
  • Beltran, Sergi
  • Fernández-Cuevas, Belén
  • Pérez-Sanz, Nuria
  • Nova-Gurumeta, Sara
  • Gut, Ivo Glynne
  • Al-Shahrour, Fátima
  • Piris, Miguel A.
  • García-Marco, J. A.
  • Sánchez-Beato, Margarita
Chronic lymphocytic leukaemia is the most prevalent leukaemia in Western countries. It is an incurable disease characterized by a highly variable clinical course. Chronic lymphocytic leukaemia is an ideal model for studying clonal heterogeneity and dynamics during cancer progression, response to therapy and/or relapse because the disease usually develops over several years. Here we report an analysis by deep sequencing of sequential samples taken at different times from the affected organs of two patients with 12- and 7-year disease courses, respectively. One of the patients followed a linear pattern of clonal evolution, acquiring and selecting new mutations in response to salvage therapy and/or allogeneic transplantation, while the other suffered loss of cellular tumoral clones during progression and histological transformation., This work was supported by the Spanish Ministry of Economy and Competence (MINECO): SAF2013-47416-R; ISCIII-MINECO AES-FEDER (Plan Estatal de I + D + I 2008–2011 and 2013–2016) (PI14/00221 (MSB), PIE14/0064 (MSB), PIE15/0081 (MAP), PI16/01294 (MAP), CIBERONC CB16/12/00291 (MAP)), Madrid Autonomous Community, B2017/BMD3778 (MAP, MSB, FA-S), F Hoffmann-La Roche (JAGM); CNIO Bioinformatics Unit work has been supported by Marie-Curie Career Integration Grant CIG334361. J.G.-R. is a recipient of a i-PFIS predoctoral fellowship (IFI14/00003); NM was supported by AECC Scientific Foundation; S.D. was supported by the Torres Quevedo subprogramme (MICINN) under grant agreement PTQ-12-05391. K.T. and J.P.-P. are supported by Severo Ochoa FPI grant doctoral fellowship by the Spanish MINECO. MSB currently holds a Miguel Servet II contract (CPII16/00024) supported by ISCIII-MINECO AES-FEDER (Plan Estatal I + D + I 2013–2016) and the Fundación de Investigación Biomédica Puerta de Hierro.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma

  • Alonso Alonso, Ruth
  • Mondéjar, Rufino
  • Martínez, Nerea
  • García Diaz, Nuria
  • Pérez, Cristina
  • Merino, David
  • Rodríguez, Marta
  • Esteve-Codina, Anna
  • Fusté, Berta
  • Gut, Marta
  • Burrows, Francis
  • Scholz, Catherine
  • Vaqué, José Pedro
  • Gualberto, Antonio
  • Piris, Miguel A.
Patients diagnosed with T-cell leukemias and T-cell lymphomas (TCLs) still have a poor prognosis and an inadequate response to current therapies, highlighting the need for targeted treatments. We have analyzed the potential therapeutic value of the farnesyltransferase inhibitor, tipifarnib, in 25 TCL cell lines through the identification of genomic and/or immunohistochemical markers of tipifarnib sensitivity. More than half of the cell lines (60%) were considered to be sensitive. Tipifarnib reduced cell viability in these T-cell leukemia and TCL cell lines, induced apoptosis and modified the cell cycle. A mutational study showed TP53, NOTCH1 and DNMT3 to be mutated in 84.6%, 69.2% and 30.0% of sensitive cell lines, and in 62.5%, 0% and 0% of resistant cell lines, respectively. An immunohistochemistry study showed that p-ERK and RelB were associated as potential biomarkers of tipifarnib sensitivity and resistance, respectively. Data from RNA-seq show that tipifarnib at IC50 after 72 h downregulated a great variety of pathways, including those controlling cell cycle, metabolism, and ribosomal and mitochondrial activity. This study establishes tipifarnib as a potential therapeutic option in T-cell leukemia and TCL. The mutational state of NOTCH1, p-ERK and RelB could serve as potential biomarkers of tipifarnib sensitivity and resistance., The research was supported by grants from the Instituto de Salud Carlos III, from the Ministerio de Economía, Industria y Competitividad [SAF2013-47416-R, CIBERONC-ISCIII, ISCIII-MINECO-AES-FEDER (Plan Estatal I + D + I 2013–2016)}.